Skip to main content

Advertisement

Table 1 Absolute counts of peripheral blood DCs in controls and in patients with CVID

From: Altered dendritic cell distribution in patients with common variable immunodeficiency

Dendritic cells per ml Healthy controls (n = 12) CVID patientsa
   Group 1a (n = 13) Group 1b (n = 9) Group 2 (n = 15) Group 3 (n = 7)
Myeloid DCs      
   Total (median) 14,361 8,432*,θ 13,475 15,267 5,568Ψ,φ
   Percentiles (25th, 75th) 11,470, 16,693 1,428, 11,330 8,378, 16,143 9,462, 18,590 4,315, 11,100
   Range 8,941–22,204 342–21,895 3,039–19,385 6,178–28,472 3,787–22,994
Plasmacytoid DCs      
   Total pDCs (median) 9,829 2,367*,λ,θ 3,647 8,980 1,403Ψ,ξ,φ
   Percentiles (25th, 75th) 8,366, 16,555 353, 5,012 2,532, 11,590 4,096, 13,367 661, 2,448
   Range 7,514–22,769 19–8,291 2,004–13,714 1,614–25,725 417–4,917
  1. aPatients were grouped according to whether their proportion of switched memory B cells was <0.4% (groups 1a, 1b) or >0.4% (group 2) of total peripheral blood lymphocytes or they had granulomatous disease (group 3). Group 1 was subdivided according to whether numbers of CD19+CD21- immature B cells were increased (group 1a) or normal (group 1b). *P < 0.001 vs controls;θP < 0.009 vs group 2; λP = 0.02 vs group 1b; ΨP < 0.01 vs controls; ξP < 0.009 vs group 1b; φP < 0.02 vs group 2. Other comparisons between each population were not statistically significant. The nonparametric Mann–Whitney U test was used for comparisons. CVID, common variable immunodeficiency.